It’s a good day to be an Seres Therapeutics Inc. (MCRB) shareholder

In the latest session, Seres Therapeutics Inc. (NASDAQ: MCRB) closed at $5.29 up 1.54% from its previous closing price of $5.21. In other words, the price has increased by $+0.08 from its previous closing price. On the day, 680076 shares were traded. MCRB stock price reached its highest trading level at $5.32 during the session, while it also had its lowest trading level at $5.17.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

Ratios:

For a deeper understanding of Seres Therapeutics Inc.’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.00 and its Current Ratio is at 3.00. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.75.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Goldman on July 23, 2021, Downgraded its rating to Sell and sets its target price to $7 from $24 previously.

Chardan Capital Markets Upgraded its Neutral to Buy on March 05, 2021, while the target price for the stock was maintained at $30.

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 31 when Ege David S. sold 5,012 shares for $7.93 per share. The transaction valued at 39,745 led to the insider holds 46,734 shares of the business.

Nutritional Health LTP Fund Ge bought 8,738,243 shares of MCRB for $27,525,465 on Jul 05. The 10% Owner now owns 5,875,711 shares after completing the transaction at $3.15 per share.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 48.25 while its Price-to-Book (P/B) ratio in mrq is 9.62.

Stock Price History:

Over the past 52 weeks, MCRB has reached a high of $9.49, while it has fallen to a 52-week low of $2.50. The 50-Day Moving Average of the stock is 6.13, while the 200-Day Moving Average is calculated to be 5.36.

Shares Statistics:

For the past three months, MCRB has traded an average of 811.86K shares per day and 592.35k over the past ten days. A total of 122.53M shares are outstanding, with a floating share count of 116.29M. Insiders hold about 0.50% of the company’s shares, while institutions hold 85.80% stake in the company. Shares short for MCRB as of Oct 13, 2022 were 4.94M with a Short Ratio of 6.81M, compared to 3.38M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 3.98% and a Short% of Float of 5.61%.

Earnings Estimates

There are 8 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.47 for the current quarter, with a high estimate of -$0.3 and a low estimate of -$0.55, while EPS last year was $0.72. The consensus estimate for the next quarter is -$0.43, with high estimates of -$0.02 and low estimates of -$0.56.

Analysts are recommending an EPS of between -$1.54 and -$2.4 for the fiscal current year, implying an average EPS of -$2.17. EPS for the following year is -$1.08, with 8 analysts recommending between $0.1 and -$2.37.

Revenue Estimates

A total of 8 analysts believe the company’s revenue will be $7M this quarter.It ranges from a high estimate of $29M to a low estimate of $1.22M. As of the current estimate, Seres Therapeutics Inc.’s year-ago sales were $126.72M, an estimated decrease of -94.50% from the year-ago figure. For the next quarter, 8 analysts are estimating revenue of $11.52M, an increase of 59.50% over than the figure of -$94.50% in the same quarter last year. There is a high estimate of $65.1M for the next quarter, whereas the lowest estimate is $1.22M.

A total of 8 analysts have provided revenue estimates for MCRB’s current fiscal year. The highest revenue estimate was $96.8M, while the lowest revenue estimate was $5.14M, resulting in an average revenue estimate of $21.23M. In the same quarter a year ago, actual revenue was $144.93M, down -85.40% from the average estimate. Based on 8 analysts’ estimates, the company’s revenue will be $140.72M in the next fiscal year. The high estimate is $322.5M and the low estimate is $20M. The average revenue growth estimate for next year is up 562.80% from the average revenue estimate for this year.